X

Drug Profile

HRS 7415

Alternative Names: HRS-7415

Latest Information Update: 04 Dec 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jiangsu Hengrui Medicine Co.
Class Antineoplastics
Mechanism of Action Protein kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Solid tumours

Most Recent Events

01 Dec 2023 Phase-I clinical trials in Solid tumours (Late-stage disease) (PO), prior to December 2023 (Jiangsu HengRui Medicine, December 2023)
15 Apr 2022 Jiangsu HengRui Medicine plans a phase I trial for Cancer (Late-stage disease, Metastatic disease) in April 2022 (PO) (NCT05318833)
08 Apr 2022 Preclinical trials in Cancer in China before April 2022 (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com